• / Free eNewsletters & Magazine
  • / My Account
Home>Search Results

Related Content

  1. Videos
  2. Articles
  1. Behind the Bullish Take on Our Top Pharma Pick

    A large generics business and niche pipeline keep Novartis ahead of the curve.

  2. An Opportunistic Pharma Pick

    Premature disappointment over the prospect of Vanda's sole drug has left investors with a compelling opportunity says Morningstar Opportunistic Investor's Stephen Ellis.

  3. Healthy Growth Prospects for This Pharma Pick

    Day 7: Growth from emerging markets as well as launched and pipeline products bode well for this pick.

  4. Big Pharma Dividends Alive and Well

    Pharmaceutical firms' lower-than-historical valuations and high-margin, patent-protected products are positive signs for investors seeking more yield.

  1. GlaxoSmithKline PLC GSK Q3 2010 Earnings Call Transcript

    Thank you, very much and thank you all for joining us on this Q3 call of GSK. I am going to take you through just some headlines on the overall performance of the Company and RnD and then Julian Heslop, our CFO will take you through some more detail before we open up for questions.

  2. GlaxoSmithKline PLC GSK Q1 2011 Earnings Call Transcript

    My name is Simon, I'm your operator today. The format of the call will be some opening remarks from Andrew and Simon and (technical difficulty)

  3. Big Pharma’s Giant Dividend Yields

     

  4. Novartis AG NVS Q1 2012 Earnings Call Transcript

    Good day and welcome to the Novartis Conference Call. At this time, I would like to turn the conference over to Mr. Joe Jimenez, CEO of Novartis. Please go ahead, sir.

1
ShareEmail
Print
Text Size
Comment
blog comments powered by Disqus
Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.